A5041933006- Reproductive Health and Contraception
- Ectopic Pregnancy Diagnosis and Management
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- Maternal and fetal healthcare
- Maternal and Perinatal Health Interventions
- Pregnancy and Medication Impact
- Global Maternal and Child Health
- Assisted Reproductive Technology and Twin Pregnancy
- Maternal Mental Health During Pregnancy and Postpartum
- Reproductive Health and Technologies
- Sexual function and dysfunction studies
- Ovarian function and disorders
- Diversity and Career in Medicine
- Pelvic floor disorders treatments
- Gynecological conditions and treatments
- Urinary Tract Infections Management
- Urinary Bladder and Prostate Research
- Male Reproductive Health Studies
- Menopause: Health Impacts and Treatments
Bayer (Finland)
2009-2023
Bayer (Germany)
2010-2023
Oregon Health & Science University
2010-2023
University of Portland
2020-2022
RELX Group (United States)
2012-2017
RELX Group (United Kingdom)
2012-2017
University of the Philippines Diliman
2017
New York City Health and Hospitals Corporation
2012
Florida College
2010
University of Florida
2010
To compare the efficacy and safety of levonorgestrel-releasing intrauterine system oral medroxyprogesterone acetate in treatment idiopathic heavy menstrual bleeding.In this multicenter, randomized, controlled study, women aged 18 years or older with bleeding (menstrual blood loss 80 mL more per cycle) were randomly assigned to six cycles either (10 mg daily for 10 days beginning on day 16 each cycle). The primary variables absolute change from baseline end study proportion successful...
To assess the safety profile of low-dose levonorgestrel intrauterine system (LNG-IUS) total content 13.5mg (average approximate release rate 8μg/24h over first year; LNG-IUS 8; Jaydess®) in adolescents.In a Phase III study 36 European centers, 304 healthy nulliparous or parous postmenarcheal adolescents (12-17years) received 8 for 12months. The primary outcome was incidence treatment-emergent adverse events (TEAEs). Secondary outcomes included: serious TEAEs, special interest, overall user...
Since its introduction in 1990, the levonorgestrel-releasing intrauterine system (LNG-IUS) has played a key role shaping healthcare landscape of women. Here we explore development first LNG-IUS (Mirena®) and early clinical trials that demonstrated potential. We highlight contraceptive therapeutic benefits Mirena®, discuss how practice been changed since other long-acting reversible methods. The history Mirena® is rich innovation also paved way to smaller systems with lower hormone doses....
To determine the pharmacokinetics of oxybutynin and its main active metabolite, N-desethyloxybutynin, after multiple dosage (5 mg/30 ml three times daily) intravesical formulation. Furthermore, to efficacy safety in symptomatic relief urge incontinence or urgency adult patients with detrusor hyperreflexia instability.Nine were randomly allocated treatment a special bladder instillation formulation placebo for two 14-day periods double-blind, cross-over manner. The third, open study period...
Objective: The aim of the study was to provide an additional, detailed description early bleeding patterns with 19.5 mg levonorgestrel-releasing intrauterine system (LNG-IUS).Methods: We conducted a pooled analysis diaries participants in previously reported phase II randomised controlled (n = 741) and III 2904), 2-year extension 707), LNG-IUS. Main outcome measures were median number and/or spotting days per 30-day reference period for 12 months influence previous contraceptive method...
Universal access to sexual and reproductive health services is essential facilitate the empowerment of women achievement gender equality. Increasing modern methods contraception can reduce incidence unplanned pregnancy decrease maternal mortality. Long-acting reversible contraceptives (LARCs) offer high contraceptive efficacy as well cost-efficacy, providing benefits for both healthcare systems. The levonorgestrel-releasing intrauterine system (LNG-IUS) first became available in 1990 with...
ObjectivesTo report placement success rate, and ease pain associated with placement, of the levonorgestrel-releasing intrauterine system (LNG-IUS) 8 using modified EvoInserter® device.Study designThis was a pooled analysis data from three previously reported Phase III studies in nulliparous (83.3%) or parous (16.7%) women aged 12–35 years (N=965). LNG-IUS placed Evolnserter®. The main outcomes assessed were success, as by healthcare professionals (HCPs), at participants, assessment device...
INTRODUCTION: The Mirena Extension Trial (MET) is a multicenter, open-label, single group study being conducted in the USA investigating contraceptive efficacy and safety of 52 mg LNG-IUS (Mirena®) during extended use for up to 8 years, with analyses planned at end Year 6, 7 8. METHODS: We recruited screened current users LNG-IUS, ≤35 years age, after minimum 4 6 months use. Eligible consenting participants underwent baseline visit 0 14 days before 5. Institutional review board approval was...
INTRODUCTION: To characterize performance of the levonorgestrel releasing intrauterine system (LNG-IUS) 52 mg (Mirena) for 8 years use (currently approved 7 years) and facilitate comparisons with LNG-IUS 19.5 13.5 mg, we estimated in vivo LNG release rates plasma/serum concentrations using a population pharmacokinetic (popPK) approach data from Mirena Extension Trial (MET) earlier clinical trials. METHODS: Previously, developed popPK model based on measured residual content removed devices...
ABSTRACT With over 30 years of use, levonorgestrel-releasing intrauterine systems (LNG-IUSs) have proven to be highly effective methods contraceptives. The active ingredient in LNG-IUS, levonorgestrel (LNG), is released directly into the uterine cavity, which causes suppression endometrial maturation and thickened cervical mucus. A variety LNG-IUS options exhibit well-established safety profiles efficacy, providing anywhere between 2 18 times lower systemic exposure when compared with...